Results 221 to 230 of about 10,910 (237)

Classification of European Illex coindetii and Loligo forbesii Squid Stocks by Trace Element Analysis of Statoliths

Fisheries Management and Ecology, Volume 33, Issue 2, Page 181-200, April 2026.
ABSTRACT We investigated whether statolith microchemistry analysis could classify ommastrephid and loliginid squid species into fishery stocks. Statolith nucleus (early life stage) and edge (life stage at time before catch) of Illex coindetii (Verany, 1839) and Loligo forbesii (Steenstrup, 1856) from various areas of the North East Atlantic Ocean and ...
Bianca T. C. Bobowski, Anne Marie Power, Finlay Burns, Pierluigi Carbonara, Danila Cuccu, Maria Cristina Follesa, Klaus Peter Jochum, Ana Moreno, Inna M. Sokolova, Maria Valls, Daniel Oesterwind   +10 more
wiley   +1 more source

Twenty‐One Years of Global Atmospheric Chlorine Inventories From Atmospheric Chemistry Experiment Fourier Transform Spectrometer (ACE‐FTS) Measurements

Journal of Geophysical Research: Atmospheres, Volume 131, Issue 5, 16 March 2026.
Abstract We present atmospheric chlorine inventories over 21 years (2004–2024) and five latitude bands (82–60°N, 60–30°N, 30°N–30°S, 30–60°S, 60–82°S) across altitudes from the surface up to 61 km. These inventories were calculated using the Atmospheric Chemistry Experiment‐Fourier Transform Spectrometer (ACE‐FTS) version 5.3 retrievals of the volume ...
N. Raymond, P. Bernath, C. Boone, M. P. Chipperfield   +3 more
wiley   +1 more source

Hydrocarbons monthly bulletin 7-1982 [PDF]

, 1982

core  

Novel p53 reactivators that are synergistic with olaparib for the treatment of gynecologic cancers with mutant p53. [PDF]

Transl Oncol
Smith LE, Padilla JL, Licor A, Steinkamp MP, Lagutina IV, Guo Y, Devor EJ, Pankratz VS, Sallmyr A, Oyebamiji OM, Choe JY, Williams GL, Leslie KK.   +12 more
europepmc   +1 more source

Examining Discordance in Perceptions of COVID-19 and Influenza Vaccine Safety During Pregnancy Among a Cohort of US Adults. [PDF]

Vaccines (Basel)
Piltch-Loeb R, Chan BXJ, Nuñez Sahr J, Teasdale C, Fleary S, Penrose K, Sanborn J, Balasubramanian S, Robertson M, Parcesepe A.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Abstract 1291: APR-246 enhances tumor immunogenicity even in the absence of p53

Cancer Research, 2022
Abstract Despite the significant success of immunotherapy, more than 40% of cancer patients remain unresponsive or exhibit an insufficient response. Well-designed combinations of targeted therapy and immunotherapy have the potential to increase effectiveness of cancer treatment and overcome the absence of response to either therapy alone.
Divya Venkatesh, Judith Michels, Cailian Liu, Sadna Budhu, Mariam M. George, Lars Abrahmsen, Roberta Zappasodi, Jedd D. Wolchok, Taha Merghoub   +8 more
openaire   +1 more source

Impact of combined MRP1 inhibition and mutant p53-targeting compound APR-246.

Journal of Clinical Oncology, 2019
e14712 Background: The tumor suppressor gene TP53 is the most frequently mutated gene in cancer. Mutant p53 protein is often expressed at high levels and accompanied with gain-of-function activities that promote tumor development and resistance towards conventional treatment.
Anna Sophia Ceder, Sofi E. Eriksson, Emarndeena Haji Cheteh, Vladimir J.N. Bykov, Lars Abrahmsen, Klas G. Wiman   +5 more
openaire   +1 more source

Abstract 4885: APR-246 cytotoxic effects are TP53 independent in endometrial cancer cell lines

Cancer Research, 2023
Abstract Background: The majority (80%) of endometrial cancer (EC) related mortality is due to high-grade tumor histology, which harbor high rates of TP53 mutations. APR-246 is a small-molecule drug designed to restore WT p53 signaling in TP53-mutant cancers and has yet to be explored in EC.
Camilla Yu, Aaron Petty, Roberto Vargas
openaire   +1 more source